Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03463057 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Study acronym: HO151DLBCL
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 37 words Publications: details revised at 1 of 1 entry Show 1 more changeShow less
    • Publications: details revised at 1 of 1 entry
  2. 4 versions Re-verified since Aug 16, 2023, no change to tracked fieldsv10-v13
  3. Primary completion date: Apr 2022 to Jan 18, 2024 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 114 to confirmed 109 · Study sites: 33 to 32 · 1 morev9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 114 to confirmed 109
    • Study sites: 33 to 32
    • Completion date: Apr 2025 to Jan 2027
  4. Study sites: 1 to 33v8
  5. Re-verified, no change to tracked fieldsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 33 to 1v6
  2. Re-verified, no change to tracked fieldsv5
  3. Eligibility criteria expanded, about 23 words Site details revised at 4 of 33 sitesv4 Show 1 more changeShow less
    • Site details revised at 4 of 33 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 32 to 33 Eligibility criteria expanded, about 40 wordsv3 Show 1 more changeShow less
    • Eligibility criteria expanded, about 40 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2018 to Aug 30, 2018 · Secondary endpoints: details revised at 5 of 5 entries · Study description expanded, about 140 words · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Apr 2018 to Aug 30, 2018
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study description expanded, about 140 words
    • Site details revised at 32 of 32 sites

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for \> 6000 patients and is manageable. The assumption of this study is that atezolizumab consolidation will result in higher disease free survival by eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy after chemoradiotherapy has shown an increase in survival.
Trial Details
NCT Number NCT03463057
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Conditions NHL, DLBCL
Enrollment 109 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov